Regen Biopharma receives USPTO Notice of Allowance for NR2F6 activity modulators patent

Regen BioPharma Inc

Notice of Allowance issued Sept 23, 2021 for patent on small molecule agonists/antagonists of NR2F6.
Invention relates to compounds that alter NR2F6 activity, a nuclear receptor involved in immune regulation.
Allowed patent strengthens Regen's IP position for its small molecule immunomodulator program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.